NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (CSE:HSM) (“HMT”, or the “Company”) is pleased to announce today that U.S. Patent No. 8,849,407, “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function,” has been granted by the US Patent Office (USPTO). Helius has an exclusive license to this patent, which is core to protecting the Portable NeuroModulation Stimulator (PoNS™) device and the associated therapeutic modality. The PoNSTM, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (“TBI”) and Multiple Sclerosis.
Helius’ patent strategy, which is being executed by Joe Capraro and his team at Proskauer Rose LLP, is to pursue patent protection for the core platform technology as well to patent protect evolving device design concepts. Helius has numerous other patent applications either in process or pending adjudication from the USPTO.
Help employers find you! Check out all the jobs and post your resume.
